MYL News Alert Mylan Inc (MYL) 56.97 12/25/2014 15:57:18

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mylan Inc (MYL) 56.97 $MYL

Mylan reports market availability of first generic Vivelle-DOT for vasomotor symptoms & vulvar and vaginal atrophy
M2 - Tue Dec 23, 5:22AM CST
Pharmaceutical company Mylan (NasdaqGS:MYL) said on Tuesday that it has unveiled its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (twice weekly) in the market.
MYL: 56.97 (+0.39), NVS: 93.91 (+0.66)

Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:51PM CST
Actavis' (ACT) antibiotic, Xydalba, which is already marketed in the U.S. under the trade name Dalvance, is a step closer to EU approval.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)

Hold On To Teva!
Investing Tricks - at Seeking Alpha - Mon Dec 22, 2:09PM CST

MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33), MNTA: 11.42 (-0.06), NVS: 93.91 (+0.66)

Mylan Launches First Generic Version of Vivelle-DOT®
PR Newswire - Mon Dec 22, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (Twice Weekly), which is the generic version of Novartis' Vivelle-DOT®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; and the prevention of postmenopausal osteoporosis.(1)
MYL: 56.97 (+0.39), NVS: 93.91 (+0.66)

5 Health Care Stocks John Paulson Is Buying Ahead of 2015
at The Street - Mon Dec 22, 6:00AM CST
Here's a closer look at five stocks Paulson & Co. bought in the most recently reported quarter.
MNK: 97.84 (-0.29), HCA: 74.89 (-0.11), COV: 103.35 (+0.57), MYL: 56.97 (+0.39), ABBV: 66.21 (+1.86)

Mylan Set to Possibly Pullback After Yesterday's Rally of 1.20%
Comtex SmarTrend(R) - Fri Dec 19, 3:45PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $56.56 to a high of $57.83. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $56.85 on volume of 7.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 56.97 (+0.39)

After Yesterday's Rally of 1.20% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Dec 19, 3:45PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $56.56 to a high of $57.83. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $56.85 on volume of 7.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 56.97 (+0.39)

Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 6:07PM CST
Pfizer (PFE) has moved its experimental Duchenne muscular dystrophy treatment into a phase II study.
RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), MYL: 56.97 (+0.39)

Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference
PR Newswire - Wed Dec 17, 8:00AM CST
Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 33rd Annual Healthcare Conference on Tuesday Jan. 13, 2015, in San Francisco.
JPM: 62.48 (unch), MYL: 56.97 (+0.39)

Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:20PM CST
Actavis plc (ACT) announced its decision to file an emergency appeal for an immediate overturn of the lower court ruling that will require the company to continue selling Namenda IR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)

Mylan (MYL) Crosses Pivot Point Resistance at $54.18
Comtex SmarTrend(R) - Mon Dec 15, 9:34AM CST
Mylan (NASDAQ:MYL) has opened bullishly above the pivot of $53.72 today and has reached the first level of resistance at $54.18. Investors may be interested in a cross of the next upside pivot targets of $55.03 and $56.34.
MYL: 56.97 (+0.39)

Teva's (TEVA) 2015 Guidance Hit By Generics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 4:20PM CST
Teva Pharmaceutical Industries Ltd (TEVA) provided a narrower-than-expected outlook for 2015.
BIIB: 340.89 (+5.13), MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)

Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 2:20PM CST
Actavis plc (ACT) may face an injunction under which the company will have to continue selling Namenda IR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)

Teva Upgraded On Strength Of Copaxone MS Drug
at Investor's Business Daily - Fri Dec 12, 9:38AM CST
Sterne Agee upgraded Israeli drug giant Teva Pharmaceutical Industries (TEVA) to buy from neutral Friday, saying the outlook for its multiple-sclerosis drug Copaxone is better than most investors think. Teva issued 2015 guidance on Thursday morning,...
MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33), MNTA: 11.42 (-0.06), NVS: 93.91 (+0.66)

Mylan Among First to Launch Generic Celebrex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 3:22PM CST
Mylan Inc. announced that it has launched the generic version of Pfizer's Celebrex.
ACT: 254.20 (-1.68), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33)

Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 2:20PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Para IV notice from TWi Pharma, seeking approval for its generic version of Supernus' Oxtellar XR in the U.S.
ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)

Mylan Launches Generic Robaxin® Injection
PR Newswire - Thu Dec 11, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Methocarbamol Injection, which is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Mylan's immediate shipment of this product supports the growth of the company's portfolio of more than 100 injectable products in the U.S.
MYL: 56.97 (+0.39)

Mylan Launches First Generic Version of Orapred ODT®
PR Newswire - Thu Dec 11, 6:00AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg, and was awarded 180 days of generic drug marketing exclusivity. This product is indicated as an anti-inflammatory or immunosuppressive agent for certain conditions; and also for the treatment of certain endocrine conditions, and for palliation of certain neoplastic conditions.
MYL: 56.97 (+0.39)

Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:50PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Paragraph IV notice from Par, which is looking to get its generic version of Supernus' Trokendi XR approved in the U.S.
ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)

Mylan Launches One of First Available Generic Versions of Celebrex® Capsules
PR Newswire - Wed Dec 10, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.(1)
MYL: 56.97 (+0.39)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 269

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 89

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 121

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Blueprint Strengthens Team with New Capital Markets Director

Updated Category News Views 114

Blueprint Bolsters Its Ranks Hiring Caitlin Novak as Managing Director marks a pivotal step for Blueprint Healthcare Real Estate Advisors. They aren't just swapping pawns; they're making a statement, beefing up their capital markets strategy with a heavy hitter seasoned in steering around fiscal pitfalls. Novak isn’t some rookie wet behind the ears—she's clocked more...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 162

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 186

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 66

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 77

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading

Top 5 Most Recently Viewed Articles

Future Tech Boosts Leadership with Mike Watkinson's Appointment

Updated Category News Views 156

Future Tech Welcomes New CRO to Boost Revenue Strategy Future Tech Enterprise, Inc., a reputable provider of technology solutions, has recently appointed Mike Watkinson as its new Chief Revenue Officer (CRO). In this role, he will be responsible for driving global revenue growth and improving sales strategies for the company. This appointment follows a recent expansion of...

Continue Reading
Supporting Careers of Migraine Sufferers: AbbVie Contest Open

Updated Category News Views 250

AbbVie Launches the Second Annual Career Catalyst Award for Migraine Sufferers AbbVie has opened the entries for the second annual AbbVie Migraine Career Catalyst Award™ contest, offering significant financial assistance to help winners achieve their career aspirations. This initiative is designed to empower individuals living with migraine in their professional...

Continue Reading
Shane Neil Joins Axis Insurance as Senior VP for Eastern Canada

Updated Category News Views 116

So, Axis Insurance shook things up back when they named Shane Neil as their Senior Vice President of Corporate Development for Eastern Canada. This guy's got over 20 years in the insurance game, having kicked off his career at Chubb and moving through some heavyweight roles since then. Traders were eyeing this appointment, knowing that big names can mean bigger moves in...

Continue Reading
Water Ways Technologies Reports Q2 2024 Financial Insights

Updated Category News Views 74

Water Ways Technologies Inc. Reports Q2 2024 Financial Results Water Ways Technologies Inc. (TSXV: WWT) has released its financial results for the second quarter of 2024. As a prominent provider of agricultural technology based in Israel, the company focuses on improving water irrigation solutions and is dedicated to fostering innovation in the agriculture industry....

Continue Reading
Celebrating Technological Excellence: Mats Karlsson's Acclaimed Achievement

Updated Category News Views 116

Icomera Honors CTO Mats Karlsson with the Polhem Prize 2025 Icomera is thrilled to announce that its Chief Technology Officer, Mats Karlsson, has been awarded the Polhem Prize 2025. This esteemed recognition is one of Sweden's highest honors for outstanding contributions to technological innovation, presented by the Swedish Association of Graduate Engineers. The...

Continue Reading